NVCR - Novocure Ltd logo

Novocure Ltd

NVCR

Novocure Ltd develops and commercializes tumor treating fields (TTFields) devices for solid tumor cancers. Its products include Optune Gio, Optune Lua, and Optune Pax, targeting conditions like glioblastoma and malignant pleural mesothelioma.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$1,864today

Score Overview

1 Year
Score
Net Growth-9.06%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth6.69%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score3.8
Net Growth-154.61%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth30.68%
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-12.68%
Net Trend50%
Net Income Consistency
Rev Growth8x
Rev Trend90%
Revenue Consistency
All Time
Score
Net Growth-33.15%
Net Trend45%
Net Income Consistency
Rev Growth21x
Rev Trend91%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Novocure Ltd has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. NVCR does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-01
$ 15.92โ€”
1 Year2025-10-01
$ 13.9813.88%
5 Years2021-10-01
$ 116.11-86.29%
10 Years2016-09-30
$ 8.5486.42%
All Time2015-10-02
$ 18.28-12.91%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 699M-$ 148M$ 440M
2025$ 655M-$ 136M$ 457M
2024$ 605M-$ 168M$ 959M
2023$ 509M-$ 207M$ 910M
2022$ 537M-$ 92M$ 969M
2021$ 535M-$ 58M$ 937M
2020$ 494M$ 19M$ 854M
2019$ 351M-$ 7M$ 326M
2018$ 248M-$ 63M$ 245M
2017$ 177M-$ 61M$ 183M
2016$ 82M-$ 131M$ 219M
IPO2015$ 33M-$ 111M$ 269M
NVCR - Novocure Ltd logo

Novocure Ltd fundamental performance

Between 2020 and 2025, revenue grew from $ 494M to $ 655M and net income went from $ 19M to -$ 136M. Revenue increased in 4 of those 5 years; net income in 2.

Between 2015 and 2025, revenue grew from $ 33M to $ 655M and net income went from -$ 111M to -$ 136M. Revenue increased in 9 of those 10 years; net income in 5.

Novocure Ltd currently holds a 5-year HDB Score of 3.8 out of 10. How the HDB Score is calculated.

Membership

Explore NVCR with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,813 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies